Subscribe To
PRLD / Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
PRLD News
By Zacks Investment Research
October 4, 2023
All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy
Prelude Therapeutics Incorporated (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Za more_horizontal
By GlobeNewsWire
April 11, 2023
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline more_horizontal
By Zacks Investment Research
March 16, 2023
Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients. more_horizontal
By GlobeNewsWire
February 9, 2023
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology co more_horizontal